As of November 6, 2026, Citius Oncology, Inc. is a publicly traded company (Nasdaq: CTOR). Citius Pharmaceuticals, Inc. reports holding 71%, a majority of its shares. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Armistice Capital (9.99%) (Schedule 13D/A, June 4, 2026).
Is this your company?
About to sign with, pay or invest in Citius Oncology, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Citius Oncology, Inc. a real, registered company?
- Citius Oncology, Inc. files with the SEC under CIK 1851484 (its SEC filings).
- Its shares are listed under the ticker CTOR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cranford, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Citius Oncology, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Citius Oncology, Inc.'s owners and officers?
Citius Oncology, Inc.: incorporated in Delaware; business address in Cranford, New Jersey; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 9.99% |
| Schedule 13D/A, 2026-06-04 | Citius Pharmaceuticals, Inc. | 71% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 9.99% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 9.99% |
| Schedule 13D/A, 2025-12-17 | Citius Pharmaceuticals, Inc. | 77.9% |
| Schedule 13G, 2025-11-14 | Armistice Capital, LLC | 9.79% |
| Schedule 13D/A, 2025-09-12 | Citius Pharmaceuticals, Inc. | 79.1% |
| Schedule 13D/A, 2025-07-25 | Citius Pharmaceuticals, Inc. | 84.3% |
Questions about who owns Citius Oncology, Inc.
Who owns Citius Oncology, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Citius Oncology, Inc.: Citius Pharmaceuticals, Inc. (71%, Schedule 13D/A, filed 2026-06-04) and Armistice Capital, LLC (9.99%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Citius Oncology, Inc.?
By the share each holder's latest filing reports, the largest holders of Citius Oncology, Inc. on this page are Citius Pharmaceuticals, Inc. (71%) and Armistice Capital, LLC (9.99%).
When did Citius Pharmaceuticals, Inc. buy into Citius Oncology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Citius Pharmaceuticals, Inc. on this page is the Schedule 13D/A, filed 2025-07-25, reporting 84.3%; its latest, Schedule 13D/A filed 2026-06-04, reports 71%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Citius Oncology, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Citius Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Citius Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Citius Oncology, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 1,700,000 shares (1.8% of shares outstanding) (Form 4/A, 2025-12-22).
- , the secretary and a director: 850,000 shares (0.91% of shares outstanding) (Form 4/A, 2025-12-22).
- , the chief medical officer: 825,000 shares (0.89% of shares outstanding) (Form 4/A, 2025-12-22).
- , the chief financial officer: 825,000 shares (0.89% of shares outstanding) (Form 4/A, 2025-12-22).
- , a director: 321,228 shares (0.35% of shares outstanding) (Form 4/A, 2025-12-22).
Shares outstanding: 92,981,204 as of 2026-08-13, from the company's latest SEC cover page.
How much has Citius Oncology, Inc. raised?
Latest IPO step: Citius Oncology, Inc. filed its final IPO prospectus, ticker CTOR (424B4, 2025-07-17).
IPO filings: 424B4, 2025-07-17, S-1, 2025-07-14, S-1/A, 2025-07-14; ticker CTOR on Nasdaq.
Keep reading
More on Citius Oncology, Inc. and the records around it.
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/citius-oncology